COMMITMENTS AND CONTINGENCIES - Narrative (Details)		3 Months Ended
	Jul. 29, 2019 USD ($)	Mar. 31, 2022 USD ($) liability	Dec. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Arkis
Loss Contingencies [Line Items]
Purchase price of business combination	$ 30,600,000
Contingent consideration, estimated fair value	25,500,000
Contingent consideration	13,100,000
Arkis | Fair Value, Inputs, Level 3 | Contingent Consideration Liability
Loss Contingencies [Line Items]
Fair value		$ 14,000,000		$ 15,400,000
Arkis | Other Long-term Liabilities | Fair Value, Inputs, Level 3 | Contingent Consideration Liability
Loss Contingencies [Line Items]
Fair value		10,284,000	$ 11,408,000	12,011,000	$ 11,746,000
Arkis | Accrued expenses and other current liabilities | Fair Value, Inputs, Level 3 | Contingent Consideration Liability
Loss Contingencies [Line Items]
Fair value		$ 3,800,000		3,400,000
Arkis | Development Milestones
Loss Contingencies [Line Items]
Contingent consideration, estimated fair value	10,000,000.0
Arkis | Commercial Sales Milestones
Loss Contingencies [Line Items]
Contingent consideration, estimated fair value	$ 15,500,000
Derma Sciences
Loss Contingencies [Line Items]
Number of contingent liabilities remaining | liability		1
Contingent consideration, maximum undiscounted payment amount		$ 3,000,000
Derma Sciences | Fair Value, Inputs, Level 3
Loss Contingencies [Line Items]
Contingent consideration, estimated fair value		200,000		200,000
Derma Sciences | Other Long-term Liabilities | Fair Value, Inputs, Level 3 | Contingent Consideration Liability
Loss Contingencies [Line Items]
Fair value		230,000	$ 230,000	$ 230,000	$ 230,000
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments
Loss Contingencies [Line Items]
Payment for contingent consideration		$ 33,300,000